Evidence map›Paper›PMID 42530772›Full record

Trial reportBreast cancer research and treatment2026

VEMORA: Vaginal Estrogen versus non-hormonal MOisturizer in women Receiving Aromatase inhibitors: a randomized, controlled trial.

Polly Niravath, Mothaffar Rimawi, Kai Sun, Hanh Mai, Akshjot Puri, Anuja Vyas, Julie Nangia, Alexys Brock, Claudette Foreman, Humaira Adnan and 10 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Polly NiravathHouston Methodist Hospital, 6445 Main Street, OPC 24, Houston, TX, 77030, USA. paniravath@houstonmethodist.org.ORCID http://orcid.org/0000-0002-0998-0274
Mothaffar RimawiBaylor College of Medicine, Houston, TX, USA.
Kai SunHouston Methodist Hospital, 6445 Main Street, OPC 24, Houston, TX, 77030, USA.
Hanh MaiHouston Methodist Hospital, 6445 Main Street, OPC 24, Houston, TX, 77030, USA.
Akshjot PuriHouston Methodist Hospital, 6445 Main Street, OPC 24, Houston, TX, 77030, USA.
Anuja VyasHouston Methodist Hospital, 6445 Main Street, OPC 24, Houston, TX, 77030, USA.
Julie NangiaBaylor College of Medicine, Houston, TX, USA.
Alexys BrockHouston Methodist Hospital, 6445 Main Street, OPC 24, Houston, TX, 77030, USA.
Claudette ForemanBaylor College of Medicine, Houston, TX, USA.
Humaira AdnanHouston Methodist Hospital, 6445 Main Street, OPC 24, Houston, TX, 77030, USA.
Marianne ShaferHouston Methodist Hospital, 6445 Main Street, OPC 24, Houston, TX, 77030, USA.
Anushka AnandHouston Methodist Hospital, 6445 Main Street, OPC 24, Houston, TX, 77030, USA.
Abyssania MogesHouston Methodist Hospital, 6445 Main Street, OPC 24, Houston, TX, 77030, USA.
Ebtesam Al NajjarHouston Methodist Hospital, 6445 Main Street, OPC 24, Houston, TX, 77030, USA.
Sunil MathurHouston Methodist Hospital, 6445 Main Street, OPC 24, Houston, TX, 77030, USA.
Danielle AntoshHouston Methodist Hospital, 6445 Main Street, OPC 24, Houston, TX, 77030, USA.
Rachel HighHouston Methodist Hospital, 6445 Main Street, OPC 24, Houston, TX, 77030, USA.
Tarrik ZaidHouston Methodist Hospital, 6445 Main Street, OPC 24, Houston, TX, 77030, USA.
Jenny ChangHouston Methodist Hospital, 6445 Main Street, OPC 24, Houston, TX, 77030, USA.
Kent OsborneBaylor College of Medicine, Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGenitourinary Syndrome of Menopause (GSM) remains a significant unmet need for postmenopausal breast cancer survivors receiving aromatase inhibitor (AI) therapy.

methodsIn this randomized, controlled, open-label clinical trial, ER+ breast cancer survivors receiving adjuvant AI therapy with symptomatic GSM were randomized to receive 24 weeks of a non-hormonal vaginal moisturizer (Replens

resultsTwenty-three patients were enrolled (vaginal estrogen [VE], n = 11; non-hormonal [NH], n = 12). Vaginal dryness and dyspareunia scores improved significantly in the VE arm compared with the NH arm (p = 0.049, p = 0.048, respectively). Vaginal pH decreased significantly with vaginal estrogen compared to non-hormonal therapy (p = 0.0286). Other domains of sexual function (libido, ability to achieve orgasm, sexual satisfaction, and relationship with partner) were not significantly different between the 2 groups. Serum estradiol levels remained low through the first 12 weeks of therapy. Two participants demonstrated estradiol elevations above threshold at 24 weeks (21.8 pg/mL and 16 pg/mL); both reported non-adherence to AI therapy preceding measurement.

conclusionIn this randomized study, vaginal estrogen provided greater improvement in vaginal dryness and dyspareunia than non-hormonal therapy in breast cancer survivors. These findings provide prospective evidence supporting symptomatic benefit with minimal systemic estrogen exposure in most patients, although larger studies with longer follow up are needed to define long-term safety and efficacy.

Indexed as

Aromatase InhibitorsBreast NeoplasmsEstrogensAdministration, IntravaginalAgedDyspareuniaFemaleHumansMiddle AgedTreatment OutcomeVaginaAromatase InhibitorsEstrogensAromatase Inhibitor-Induced side effectsBreast cancer survivorshipGenitourinary syndrome of menopauseHormone receptor positive breast cancerVaginal estradiol treatment

Identifiers

PMID42530772

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.